



IFW

PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Docket No: Q95592

Sang-Joon LEE, et al.

Appln. No.: 10/585,631

Group Art Unit: Unknown

Confirmation No.: Unknown

Examiner: Unknown

Filed: July 11, 2006

For: PHARMACEUTICAL COMPOSITION OF AMLODIPINE MALEATE HAVING
ENHANCED STABILITY

INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. §§ 1.97 and 1.98

MAIL STOP AMENDMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure under 37 C.F.R. § 1.56, Applicant hereby notifies the U.S. Patent and Trademark Office of the documents which are listed on the attached PTO/SB/08 A & B (modified) form and/or listed herein and which the Examiner may deem material to patentability of the claims of the above-identified application.

1. EP 0 089 167 B1, published September 21, 1983 to Pfizer Corporation.
2. U.S. Patent No. 4,879,303 issued November 7, 1989 to Davison et al.
3. U.S. Patent No. 6,919,087 B2 issued July 19, 2005 to Lemmens et al.
4. KR 10-2002-0076561 A, published October 11, 2002 to Han Mi Pharm. Ind. Company Limited with English Abstract.

Sang-Joon LEE, et al.
U.S. Appln. No.: 10/585,631
INFORMATION DISCLOSURE STATEMENT

5. KR 10-2003-0081006 A, published October 17, 2003 to Hanlim Pharmaceutical Company, Limited with English Abstract.
6. KR 10-2004-0011752 A, published February 11, 2004 to CJ Corporation with English Abstract.
7. KR 10-2004-0017380 A, published February 27, 2004 to CJ Corporation with English Abstract.
8. KR 10-2004-0072363 A, published August 18, 2004 to Daewoong Company, Limited with English Abstract.
9. G. Ragno et al., "Design and monitoring of photostability systems for amlodipine dosage forms", International Journal of Pharmaceutics, 265, (2003), pp. 125-132.

One copy of each of the listed documents is submitted herewith, except for the following:
U.S. patents 4,879,303 and 6,919,087.

The present Information Disclosure Statement is being filed: (1) No later than three months from the application's filing date; (2) Before the mailing date of the first Office Action on the merits (whichever is later); or (3) Before the mailing date of the first Office Action after filing a request for continued examination (RCE) under §1.114, and therefore, no Statement under 37 C.F.R. § 1.97(e) or fee under 37 C.F.R. § 1.17(p) is required.

The submission of the listed documents is not intended as an admission that any such document constitutes prior art against the claims of the present application. Applicant does not waive any right to take any action that would be appropriate to antedate or otherwise remove any listed document as a competent reference against the claims of the present application.

Sang-Joon LEE, et al.
U.S. Appln. No.: 10/585,631
INFORMATION DISCLOSURE STATEMENT

The USPTO is directed and authorized to charge all required fees, except for the Issue Fee and the Publication Fee, to Deposit Account No. 19-4880. Please also credit any overpayments to said Deposit Account.

Respectfully submitted,



Sunhee Lee
Registration No. 53,892

SUGHRUE MION, PLLC
Telephone: (202) 293-7060
Facsimile: (202) 293-7860

WASHINGTON OFFICE

23373

CUSTOMER NUMBER

Date: October 2, 2006

Substitute for Form 1449 A & B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Complete if Known

Application Number	10/585,631
Confirmation Number	Unknown
Filing Date	July 11, 2006
First Named Inventor	Sang-Joon LEE
Art Unit	Unknown
Examiner Name	Unknown
Attorney Docket Number	Q95592

Sheet 1 of 1

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document
		Number	Kind Code ² (if known)		
		US 4,879,303		11/07/1989	Davidson et al.
		US 6,919,087		07/19/2005	Lemmens et al.
		US			
		US			
		US			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Translation ⁶
		Country Code ³	Number ⁴	Kind Code ⁵ (if known)			
		EP	0 089 167	B1	09/21/1983	Pfizer Corporation	
		KR	10-2002-0076561	A	10/11/2002	Han Mi Pharm. Ind. Co., Ltd.	English Abstract
		KR	10-2003-0081006	A	10/17/2003	Hanlim Pharmaceutical Co., Ltd.	English Abstract
		KR	10-2004-0011752	A	02/11/2004	CJ Corporation	English Abstract
		KR	10-2004-0017380	A	02/27/2004	CJ Corporation	English Abstract
		KR	10-2004-0072363	A	08/18/2004	Daewoong Company, Limited	English Abstract

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city, and/or country where published.	Translation ⁶
		G. Ragno et al., "Design and monitoring of photostability systems for amlodipine dosage forms", International Journal of Pharmaceutics, 265, (2003), pp. 125-132.	

Examiner Signature

Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²See Kind Codes of USPTO Patent Documents at www.uspto.gov, MPEP 901.04 or follow the hyperlink from the title of the document to the intranet. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to indicate here if English language Translation is attached.